TG Therapeutics Loss Submission Form

See If You Qualify For Monetary Reward

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

Submit Transaction Detail Now (Optional)

- OR -

    An attorney-client relationship is not created with the submission of this form, nor an obligation on the part of Levi & Korsinsky or you to file a lead plaintiff motion in this matter . The information you submit is held as confidential. If, in its sole discretion, Levi & Korsinsky believes that you might be an appropriate lead plaintiff candidate, Levi & Korsinsky will contact you to discuss the matter and whether to establish an attorney client relationship. By submitting this form, you are authorizing us to contact you regarding this case and/or future cases. Additionally, by submitting this form, you agree to receive an email providing you with login details for CORE (Compensation Recovery Monitoring System) to help you monitor and track your securities. This is a complimentary service. Thank you for submitting your details to Levi & Korsinsky.

    FAX: 212-363-7171

    Levi & Korsinsky, LLP announces that a TGTX class action lawsuit has been filed on behalf of investors who purchased TG Therapeutics, Inc. (TGTX) securities between January 15, 2020 and May 31, 2022. For more on the TGTX Lawsuit please contact us today.

    According to the TG Therapeutics, Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:

    (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company’s therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib’s clinical and/or commercial prospects; and (iv) therefore, the Company’s public statements were materially false and misleading at all relevant times.

    If you suffered a loss in TG Therapeutics, Inc. you have until September 16, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.